Resolution Therapeutics has revealed positive interim six-month data from its Phase I/II EMERALD trial evaluating RTX001, an investigational autologous engineered regenerative macrophage therapy (RMT), in patients with end-stage liver disease (ESLD). The data showed a signal of efficacy on clinical outcomes of death, liver transplant and hepatic… Read More
Strand Therapeutics has dosed the first patients in its ASCENT-1 Phase I clinical trial of STX-003, an intravenously delivered self-replicating mRNA therapy designed to selectively express IL-12 within tumours while restricting expression in healthy tissue. This is the first clinical evaluation of Strand’s SignalLock genetic circuitry, designed… Read More
Biotechnology company TILT Biotherapeutics has presented encouraging results for its TILT-123 therapy at the European Society for Medical Oncology (ESMO) Congress 2026. The company reported on the Phase Ib portion of its PROTA study, which is evaluating TILT-123 (igrelimogene litadenorepvec) in combination with MSD’s anti-PD-1 therapy Keytruda… Read More
Microbiotica has presented clinical data with encouraging efficacy from its Phase Ib MELODY-1 trial of MB097, a precision microbiome therapeutic for patients with advanced melanoma. The data were presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2026. The MELODY-1 trial… Read More
Bionyra Pharma has announced positive interim results from its ongoing Phase I first-in-human study of BYN-002 (TL-001), a long-acting anti-TL1A monoclonal antibody that is in development to treat inflammatory bowel disease (IBD) and other TL1A-driven diseases. The data are being presented in a late-breaking poster at United… Read More
Zealand Pharma has shared positive Phase I multiple ascending dose (MAD) topline results for the company’s novel Kv1.3 ion channel blocker, ZP9830. The MAD part of the first-in-human, single-centre, randomised, double-blind, placebo-controlled Phase I trial was designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple… Read More
Mission Therapeutics has dosed the first patient in its Phase Ib proof-of-mechanism study of MTX325 in patients with Parkinson’s disease (PD). MTX325 is a first-in-class, highly potent and selective, orally bioavailable and brain-penetrant inhibitor of the deubiquitinating enzyme (DUB) USP30. It has been designed to… Read More
In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader (MGD), was shown to normalise multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers. Monte Rosa Therapeutics announced the finding along with other positive data from GFORCE-1, a Phase I study evaluating MRT-8102, which… Read More
Ona Therapeutics has progressed to a Phase Ia clinical development of its lead first-in-class antibody-drug conjugate (ADC), ONA-255, for the treatment of advanced cancers. The company says that more than half of the patients planned for the study have already been enrolled, with the trial continuing to… Read More
The final patient has been treated in EMERALD, Resolution Therapeutics’ Phase I/II clinical trial evaluating its engineered Regenerative Macrophage Therapy (RMT), RTX001, in patients with end-stage liver disease (ESLD) and a history of decompensated liver cirrhosis. Liver transplantation remains the only disease-modifying treatment option for patients with… Read More
Teitur Trophics has announced successful results from its Phase I clinical trial of lead asset TT-P34 in healthy volunteers and patients with early-stage Parkinson’s disease (PD). The data show TT-P34 crosses the blood-brain barrier, leading to robust, dose-dependent exposure within the brain and central nervous system (CNS). Read More
Transgene and NEC Corporation have reported sustained 100% three-year disease-free survival (DFS) in patients treated with TG4050 in the Phase I part of a randomised Phase I/II trial. TG4050 is the first individualised neoantigen therapeutic vaccine (INTV) based on the myvac platform. It is… Read More
Cancer Research UK and KisoJi Biotechnology have launched a new Phase I/IIa clinical trial for people with selected TROP2-expressing solid tumours. The study will evaluate the effectiveness and safety of KisoJi’s lead asset, KJ-103, a naked anti-TROP2 antibody. TROP2 is a transmembrane glycoprotein involved in… Read More
Skylark Bio has dosed the first patient in the SONIX Phase I/II clinical trial evaluating SKY-GJB2, its investigational inner-ear-targeted gene therapy for GJB2-mediated hearing loss. “Dosing the first patient in SONIX brings us one step closer to a future where children born with genetic hearing loss have new… Read More
Radiopharmaceuticals company Oncoinvent has announced the publication of clinical dosimetry data for Radspherin in ovarian and colorectal cancer in the Journal of Nuclear Medicine. The publication reports results from nine patients enrolled in the dosimetry cohorts of the Phase I Radspherin studies, which… Read More
Dispatch Bio has dosed the first participant in a Phase I clinical trial evaluating the safety and efficacy of DISP-10 in adult participants with advanced gastrointestinal (GI) cancers, including colorectal cancer, gastric adenocarcinoma, oesophageal adenocarcinoma, and gastroesophageal adenocarcinoma. The participant was treated with both DV-10 and ide-cel… Read More
